Alaunos Therapeutics
41
1
1
19
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
19.5%
8 terminated/withdrawn out of 41 trials
70.4%
-16.1% vs industry average
5%
2 trials in Phase 3/4
53%
10 of 19 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (41)
Long-Term Follow-Up of Recipient of Gene Transfer Research
Role: collaborator
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Role: lead
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
Role: lead
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
Role: lead
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
Role: lead
Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.
Role: lead
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
Role: lead
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
Role: lead
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Role: lead
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Role: lead
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
Role: lead
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
Role: lead
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
Role: collaborator
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
Role: collaborator
Study of ZIO-201 in Advanced Sarcoma
Role: lead
A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma
Role: lead
A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
Role: lead
A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b
Role: lead
Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma
Role: lead
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma
Role: lead